Trial
NCT05757843
Using Circulating Tumor DNA to Personalize Duration of Consolidation Durvalumab
Phase IIWITHDRAWNOTHER/UNKNOWNConfidence: LOW
Sponsor
Indiana University
Collaborators
—
Condition
NSCLC, Stage III
Intervention
Signatera ctDNA test
Why stopped
Unable to identify patients who meet eligibility requirements of tissue needed for analysis.
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2024-09-19